Document is current
Any future updates will be listed below
-
Authors
Piera Líndez, Pau https://orcid.org/0000-0002-3058-5666
Danielsen, Lasse Schnell https://orcid.org/0009-0006-2084-6363
Kovačić, Iva https://orcid.org/0009-0000-9974-5376
Pielies Avellí, Marc
Nesme, Joseph
Jensen, Lars Juhl
Andersen, Jakob Nybo https://orcid.org/0000-0003-2860-7982
Sørensen, Søren Johannes https://orcid.org/0000-0001-6227-9906
Rasmussen, Simon https://orcid.org/0000-0001-6323-9041
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF20OC0062223)
Novo Nordisk Fonden (NNF14CC0001)
Novo Nordisk Fonden (NNF23SA0084103)
Novo Nordisk Fonden (NNF20OC0062223)
Novo Nordisk Fonden (NNF23SA0084103)
Novo Nordisk Fonden (NNF20OC0062223)
Novo Nordisk Fonden (NNF14CC0001)
Novo Nordisk Fonden (NNF20OC0062223)
Novo Nordisk Fonden (NNF20OC0062223)
Novo Nordisk Fonden (NNF23SA0084103)
Novo Nordisk Fonden (NNF20OC0062223)
- License Information
-
More Information
Article History
Received: 27 March 2025
Accepted: 7 January 2026
First Online: 4 February 2026
Competing interests
: S.R. is the founder and owner of the Danish company BioAI. S.R has received a research grant and performed consulting for Sidera Bio ApS. The remaining authors declare no competing interests.
